ULTRAGENYX PHARMACEUTICAL INC. Operating Cash Flow
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Operating Cash Flow of -$294.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-05
- ULTRAGENYX PHARMACEUTICAL INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$97.00M.
- ULTRAGENYX PHARMACEUTICAL INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$197.00M.
- ULTRAGENYX PHARMACEUTICAL INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$99.83M.
- ULTRAGENYX PHARMACEUTICAL INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$91.17M.
- ULTRAGENYX PHARMACEUTICAL INC. net cash provided by (used in) operating activities for fiscal 2025 was -$466.00M.
- ULTRAGENYX PHARMACEUTICAL INC. net cash provided by (used in) operating activities for fiscal 2024 was -$414.00M.
- ULTRAGENYX PHARMACEUTICAL INC. net cash provided by (used in) operating activities for fiscal 2023 was -$475.00M.
- ULTRAGENYX PHARMACEUTICAL INC. net cash provided by (used in) operating activities for fiscal 2022 was -$380.46M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed | Net Cash Provided by (Used in) Operating Activities 47 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$97.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$294.00M 10-Q · filed 2026-08-05 | -$393.83M derived: sum of 3 quarters · filed 2026-08-05 | -$485.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | -$197.00M 10-Q · filed 2026-05-06 | -$296.83M derived: sum of 2 quarters · filed 2026-05-06 | -$388.00M derived: sum of 3 quarters · filed 2026-05-06 | -$497.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | -$99.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | -$191.00M derived: sum of 2 quarters · filed 2026-02-18 | -$300.00M derived: sum of 3 quarters · filed 2026-08-05 | -$466.00M 10-K · filed 2026-02-18 | ||||
| 2025-09-30 | -$91.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$200.17M derived: sum of 2 quarters · filed 2026-08-05 | -$366.17M 10-Q · filed 2025-11-05 | -$445.49M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | -$109.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$275.00M 10-Q · filed 2026-08-05 | -$274.75M 10-Q · filed 2025-08-06 | -$354.31M derived: sum of 3 quarters · filed 2026-08-05 | -$421.31M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-03-31 | -$166.00M 10-Q · filed 2026-05-06 | -$166.47M 10-Q · filed 2025-05-07 | -$245.31M derived: sum of 2 quarters · filed 2026-05-06 | -$312.31M derived: sum of 3 quarters · filed 2026-05-06 | -$389.27M derived: sum of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | -$79.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | -$146.31M derived: sum of 2 quarters · filed 2026-02-18 | -$223.27M derived: sum of 3 quarters · filed 2026-02-18 | -$414.00M 10-K · filed 2026-02-18 | -$414.19M 10-K · filed 2025-02-19 | |||
| 2024-09-30 | -$67.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$143.96M derived: sum of 2 quarters · filed 2025-11-05 | -$334.69M 10-Q · filed 2025-11-05 | -$418.78M derived: sum of 4 quarters · filed 2026-02-18 | ||||
| 2024-06-30 | -$76.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$267.69M 10-Q · filed 2025-08-06 | -$351.79M derived: sum of 3 quarters · filed 2026-02-18 | -$469.66M derived: sum of 4 quarters · filed 2026-02-18 | ||||
| 2024-03-31 | -$190.73M 10-Q · filed 2025-05-07 | -$274.82M derived: sum of 2 quarters · filed 2026-02-18 | -$392.70M derived: sum of 3 quarters · filed 2026-02-18 | -$508.86M derived: sum of 4 quarters · filed 2026-02-18 | ||||
| 2023-12-31 | -$84.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | -$201.97M derived: sum of 2 quarters · filed 2026-02-18 | -$318.13M derived: sum of 3 quarters · filed 2026-02-18 | -$475.00M 10-K · filed 2026-02-18 | -$474.81M 10-K · filed 2024-02-21 | |||
| 2023-09-30 | -$117.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$234.03M derived: sum of 2 quarters · filed 2024-11-06 | -$390.90M 10-Q · filed 2024-11-06 | -$481.24M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2023-06-30 | -$116.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | -$273.03M 10-Q · filed 2024-08-02 | -$363.37M derived: sum of 3 quarters · filed 2025-02-19 | -$458.71M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2023-03-31 | -$156.87M 10-Q · filed 2024-05-03 | -$247.21M derived: sum of 2 quarters · filed 2025-02-19 | -$342.55M derived: sum of 3 quarters · filed 2025-02-19 | -$419.81M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2022-12-31 | -$90.34M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | -$185.69M derived: sum of 2 quarters · filed 2025-02-19 | -$262.94M derived: sum of 3 quarters · filed 2025-02-19 | -$380.46M 10-K · filed 2025-02-19 | ||||
| 2022-09-30 | -$95.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$172.60M derived: sum of 2 quarters · filed 2023-11-03 | -$290.12M 10-Q · filed 2023-11-03 | -$344.47M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-06-30 | -$77.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | -$194.78M 10-Q · filed 2023-08-04 | -$249.12M derived: sum of 3 quarters · filed 2024-02-21 | -$308.77M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-03-31 | -$117.52M 10-Q · filed 2023-05-05 | -$171.87M derived: sum of 2 quarters · filed 2024-02-21 | -$231.51M derived: sum of 3 quarters · filed 2024-02-21 | -$296.87M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2021-12-31 | -$54.34M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | -$113.99M derived: sum of 2 quarters · filed 2024-02-21 | -$179.35M derived: sum of 3 quarters · filed 2024-02-21 | -$338.69M 10-K · filed 2024-02-21 | ||||
| 2021-09-30 | -$59.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$125.00M derived: sum of 2 quarters · filed 2022-11-03 | -$284.35M 10-Q · filed 2022-11-03 | -$346.80M derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2021-06-30 | -$65.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-29 | -$224.70M 10-Q · filed 2022-07-29 | -$287.15M derived: sum of 3 quarters · filed 2023-02-17 | -$349.12M derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2021-03-31 | -$159.35M 10-Q · filed 2022-05-06 | -$221.80M derived: sum of 2 quarters · filed 2023-02-17 | -$283.76M derived: sum of 3 quarters · filed 2023-02-17 | -$196.41M derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2020-12-31 | -$62.45M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | -$124.42M derived: sum of 2 quarters · filed 2023-02-17 | -$37.07M derived: sum of 3 quarters · filed 2023-02-17 | -$132.22M 10-K · filed 2023-02-17 | ||||
| 2020-09-30 | -$61.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $25.38M derived: sum of 2 quarters · filed 2021-11-03 | -$69.77M 10-Q · filed 2021-11-03 | -$141.81M derived: sum of 4 quarters · filed 2022-02-15 | ||||
| 2020-06-30 | $87.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | -$7.80M 10-Q · filed 2021-08-03 | -$79.84M derived: sum of 3 quarters · filed 2022-02-15 | -$168.35M derived: sum of 4 quarters · filed 2022-02-15 | ||||
| 2020-03-31 | -$95.15M 10-Q · filed 2021-05-05 | -$167.19M derived: sum of 2 quarters · filed 2022-02-15 | -$255.70M derived: sum of 3 quarters · filed 2022-02-15 | -$344.76M derived: sum of 4 quarters · filed 2022-02-15 | ||||
| 2019-12-31 | -$72.04M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | -$160.54M derived: sum of 2 quarters · filed 2022-02-15 | -$249.61M derived: sum of 3 quarters · filed 2022-02-15 | -$345.38M 10-K · filed 2022-02-15 | ||||
| 2019-09-30 | -$88.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-27 | -$177.57M derived: sum of 2 quarters · filed 2020-10-27 | -$273.34M 10-Q · filed 2020-10-27 | -$329.20M derived: sum of 4 quarters · filed 2021-02-12 | ||||
| 2019-06-30 | -$89.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | -$184.84M 10-Q · filed 2020-07-30 | -$240.69M derived: sum of 3 quarters · filed 2021-02-12 | -$309.85M derived: sum of 4 quarters · filed 2021-02-12 | ||||
| 2019-03-31 | -$95.78M 10-Q · filed 2020-05-07 | -$151.63M derived: sum of 2 quarters · filed 2021-02-12 | -$220.78M derived: sum of 3 quarters · filed 2021-02-12 | -$296.86M derived: sum of 4 quarters · filed 2021-02-12 | ||||
| 2018-12-31 | -$55.85M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | -$125.01M derived: sum of 2 quarters · filed 2021-02-12 | -$201.09M derived: sum of 3 quarters · filed 2021-02-12 | -$290.57M 10-K · filed 2021-02-12 | ||||
| 2018-09-30 | -$69.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | -$145.24M derived: sum of 2 quarters · filed 2019-11-06 | -$234.71M 10-Q · filed 2019-11-06 | -$316.54M derived: sum of 4 quarters · filed 2020-02-14 | ||||
| 2018-06-30 | -$76.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-02 | -$165.56M 10-Q · filed 2019-08-02 | -$247.38M derived: sum of 3 quarters · filed 2020-02-14 | -$309.37M derived: sum of 4 quarters · filed 2020-02-14 | ||||
| 2018-03-31 | -$89.48M 10-Q · filed 2019-05-07 | -$171.30M derived: sum of 2 quarters · filed 2020-02-14 | -$233.29M derived: sum of 3 quarters · filed 2020-02-14 | |||||
| 2017-12-31 | -$81.82M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-14 | -$143.82M derived: sum of 2 quarters · filed 2020-02-14 | -$253.84M 10-K · filed 2020-02-14 | |||||
| 2017-09-30 | -$61.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | -$172.02M 10-Q · filed 2018-11-06 | ||||||
| 2017-06-30 | -$110.03M 10-Q · filed 2018-08-03 | |||||||
| 2016-12-31 | -$160.97M 10-K · filed 2019-02-20 | |||||||
| 2014-09-30 | -$11.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | -$21.56M derived: sum of 2 quarters · filed 2014-11-10 | -$29.89M 10-Q · filed 2014-11-10 | |||||
| 2014-06-30 | -$10.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | -$18.86M 10-Q · filed 2014-08-11 | ||||||
| 2014-03-31 | -$8.34M 10-Q · filed 2014-05-12 | -$58.72M 10-Q · filed 2014-05-12 | ||||||
| 2013-09-30 | -$6.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | -$15.13M derived: sum of 2 quarters · filed 2014-11-10 | -$21.43M 10-Q · filed 2014-11-10 | |||||
| 2013-06-30 | -$8.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | -$14.68M 10-Q · filed 2014-08-11 | ||||||
| 2013-03-31 | -$6.29M 10-Q · filed 2014-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |